The aim of this randomized, open-labeled trial was to compare the incidence of acute rejection after an early (3 mo posttransplantation) withdrawal of cyclosporine (CsA) or mycophenolate mofetil (MMF) in renal transplantation. Among 218 eligible recipients, 108 nonsensitized, rejection-free patients who were under a triple drug regimen (CsA-MMF-prednisone) and had received a first kidney from a deceased donor were enrolled. At 3 mo after graft, they were gradually withdrawn from CsA (MMF group, n ‫؍‬ 54) or MMF (CsA group, n ‫؍‬ 54). A graft biopsy and a pharmacokinetic study of CsA and mycophenolic acid were systematically performed before the randomization. At 1 yr, graft and patient survival rates were 100% in each group. Renal function was improved in the MMF group compared with the CsA group (Cockcroft calculated clearance 64.7 ؎ 18.7 versus 56.5 ؎ 18.0 ml/min; P ‫؍‬ 0.023). However, the probability of acute rejection was higher in the MMF group (18.5 versus 5.6%; P ‫؍‬ 0.045). The 10 patients who developed acute rejection after CsA withdrawal had a significantly higher incidence of borderline changes on the randomization biopsy than the 44 rejection-free patients (five of 10 versus eight of 44; P ‫؍‬ 0.034), and they displayed a lower area under the curve of mycophenolic acid (43 ؎ 9 versus 58 ؎ 22 mg/h per L; P ‫؍‬ 0.045). Multivariate analysis confirmed that borderline changes and area under the curve of mycophenolic acid were significant risk factors of acute rejection after CsA discontinuation. It is concluded that a systematic graft biopsy and a pharmacokinetic study of mycophenolic acid are needed to reduce the risk for acute rejection after CsA withdrawal.
C alcineurin inhibitors (cyclosporine [CsA] or tacrolimus) remain pivotal immunosuppressive drugs in renal transplantation. However, these molecules carry serious side effects, such as hypertension, dyslipidemia, and nephrotoxicity. These factors, especially nephrotoxicity, are involved in chronic allograft dysfunction, which is a major stake in the long-term outcome. Thus, CsA minimization or withdrawal has been evaluated by numerous authors. A metaanalysis of the studies that investigated CsA discontinuation under azathioprine (AZA) and prednisone (P) reported a higher rate of acute rejection (AR) but no deleterious effect on graft survival (1) , although the trials were relatively heterogeneous. The increased risk for AR has been the main limiting factor to CsA withdrawal under AZA and P after kidney transplantation.
In a more recent era, mycophenolate mofetil (MMF), which has been proved to reduce significantly the incidence of AR in association with CsA as compared with AZA (2-4), has raised a new interest for CsA discontinuation. Initially, several authors reported their retrospective experience of the conversion from CsA to MMF in patients who developed CsA nephrotoxicity, showing a significant improvement of renal function without AR after CsA withdrawal (5) (6) (7) . In stable renal transplant recipients, CsA withdrawal under MMF was also found to be a safe procedure on the basis of the risk of AR and renal function (8, 9) , although histologic deterioration was observed in 50% of patients (10) . Finally, the incidence of AR after CsA discontinuation under MMF was evaluated in three randomized trials (11) (12) (13) . The risk for AR was found to be significantly increased in two of these studies (11, 12) , and a trend to a higher incidence was shown in the third one (13) . However, renal function, hypertension, and lipid profile were improved, especially in patients who were withdrawn successfully from CsA.
We recently completed a prospective, randomized trial that compared the incidence of AR after an early CsA or MMF discontinuation in de novo renal transplant patients who received a triple drug regimen that consisted of CsA, MMF, and steroids. As a sizable proportion of patients developed AR after CsA discontinuation, we here point out the risk factors of AR rejection after CsA withdrawal.
Materials and Methods
The aim of the study was to compare the risk for AR during the first year posttransplantation, after an early (3 mo posttransplantation) CsA or MMF withdrawal in patients who received a kidney transplant and received a triple drug regimen with CsA (Neoral, Novartis), MMF (Cellcept, Roche), and P.
Study Group
Among 218 eligible recipients, 108 patients were enrolled in a randomized, open-labeled trial when they met the following criteria: (1) First cadaveric kidney transplantation; (2) panel reactive antibodies Ͻ30%; (3) no AR during the first 3 mo after graft; (4) triple immunosuppressive drug regimen with P, MMF (Ն1.5 g/d), and CsA (Ն3 mg/kg per day and trough level Ն100 ng/ml) at the time of randomization; and (5) stable renal function defined by a serum creatinine (SCr) Ͻ2.5 mg/dl. The study was approved by the ethical committee, and all patients gave their informed consent for participation. All patients completed 1 yr of follow-up. The investigators adhered to the Declaration of Helsinki. During the study period, 110 eligible patients were not included. Reasons for noninclusion were AR during the first 3 mo after graft (n ϭ 35), nonoptimal dosage and/or side effects of immunosuppressive drugs (n ϭ 15), impaired renal function (SCr Ͼ2.5 mg/dl; n ϭ 12), early failure of the graft or death (n ϭ 8), refusal to participate (n ϭ 22), and other reasons (n ϭ 18).
Immunosuppressive Protocol
All of the patients received the same immunosuppressive regimen during the first 3 mo posttransplantation. Briefly, antithymocyte globulins (ATG) (Fresenius) induction was given for 5 d (up to 10 d in case of delayed graft function) at a dose of 3 mg/kg per day associated with P at a dose of 1 mg/kg per day for the first 2 wk then tapered down (5 mg weekly) to reach 0.10 to 0.15 mg/kg per day at month 6; MMF at a dose of 2 g per day; and a delayed introduction of CsA (1 d before ATG withdrawal) at a dose of 4 to 6 mg/kg per day then adjusted to maintain trough levels between 100 and 300 ng/ml.
Randomization and Trial Design
At 3 mo posttransplantation, all of the patients underwent a graft biopsy and a determination of the area under curve (AUC 0-12 ) of CsA (blood sample collected at 0, 2, 4, 6, 8, 10, and 12 h) and mycophenolic acid (MPA) (blood samples collected at 0, 1, 2, 4, 6, 8, 10, and 12 h) by enzymatic methods (Figure 1 ). When the graft biopsy was free from AR according to the Banff classification (14) , they were randomized (1:1 ratio) and converted from the triple-drug regimen to two dual therapies. Borderline changes as defined in the Banff classification (mild tubulitis Ͻ4 mononuclear cells/tubular cross and interstitial infiltrate) were not an exclusion criterion. Thus, either MMF or CsA was withdrawn progressively between months 3 and 4 (25% reduction of the dose, weekly), and the patients remained on CsA-P (CsA group, n ϭ 54) or MMF-P (MMF group, n ϭ 54). The pretransplantation characteristics of the two groups, renal function, and immunosuppression before randomization were similar as described in Tables 1 and 2 .
Treatment of AR
During the follow-up period, all AR (Banff Ն1) were confirmed by biopsy and treated by steroid pulses (1 g/d for 3 d). Then the patients were reverted to a triple-drug regimen, and either CsA or MMF was re-introduced. When AR were steroid resistant, CsA was switched to tacrolimus (FK; Fujisawa).
Statistical Analyses
The primary efficacy variable was the occurrence of a first biopsyproven AR. We tested the hypothesis of a unilateral equivalence for an expected incidence of AR of 10% in the CsA group. With a noninferiority limit of 15%, the number of patients to include in the study was 98 (49 in each group), for ␣ ϭ 0.05 and ␤ ϭ 0.80. Thus, 108 patients were enrolled to take into account a 10% rate of nonassessable patients for the intention-to-treat analysis and randomized 1:1.
Categorical variables were expressed as number and percentage and compared by the 2 test. Continuous variables were expressed as mean Ϯ SD and compared with the t test. Survival curves of graft and patient, as well as the probability of AR, were generated by the Kaplan-Meier method and compared by the log rank test. Univariate Cox regression analysis was used to assess the risk factors for AR. Factors that had P Ͻ 0.05 on univariate analysis were further entered into the multivariate Cox regression analysis. P Ͻ 0.05 was considered significant. Correlation analysis was carried out by the Pearson coefficient. All of the statistical tests were performed with SPSS software, version 9.0 (SPSS, Chicago, IL).
Results

AR Incidence and Graft Function
No rejection occurred during the CsA or MMF withdrawal period, from randomization up to 4 mo posttransplantation ( Figure 2 ). After randomization, the incidence of AR was significantly increased after CsA withdrawal in the MMF group (18.5 versus 5.6% in the CsA group; P ϭ 0.045) at 1 yr, as depicted in the Figure 2 . AR occurred early after CsA was stopped (52 Ϯ 45 d), with eight of 10 patients experiencing rejection within 2 mo of complete CsA discontinuation. Of note, no AR occurred during the period of stepwise CsA reduction. According to the Banff classification, among the 10 AR in the MMF group nine were grade 1 and one was grade 2. In the three AR of the CsA group, two were grade 1 and one was grade 2. The characteristics of the 13 patients who experienced rejection are summarized in the Table 3 . At 1 yr posttransplantation, graft and patient survivals were 100% in each group. The intention-to-treat analysis showed that the patients in the MMF group had better renal function as indicated by a trend to a lower SCr (1.4 Ϯ 0.7 versus 1.6 Ϯ 0.5 mg/dl; P ϭ 0.106) and a significantly higher Cockroft calculated clearance (64.7 Ϯ 18.7 versus 56.5 Ϯ 18.0 ml/min; P ϭ 0.023). However, despite their low histologic grade, these AR had a significant deleterious impact on the renal function at 1 yr. Actually, in the MMF group, the 10 patients who experienced AR had a higher SCr Figure 1 . Design of the study. compared with the 44 rejection-free patients (2.6 Ϯ 0.9 versus 1.2 Ϯ 0.2 mg/dl; P Ͻ 0.001).
Risks Factors for Rejection after CsA Discontinuation
The significantly higher incidence of AR in the MMF group and their deleterious impact on renal function underline the need to identify potential risk factors for AR after CsA withdrawal. Thus, among the patients of the MMF group, we compared pretransplantation and prerandomization (3 mo posttransplantation) characteristics of the 10 patients who experienced AR with the 44 who did not (Table 4 ). The incidence of borderline changes on the randomization biopsy was significantly increased in the subgroup of patients who developed AR after CsA withdrawal (five of 10 versus eight of 44; P ϭ 0.034), and they displayed lower trough levels (1.9 Ϯ 1.0 versus 2.7 Ϯ 1.2 mg/L; P ϭ 0.072) and AUC 0-12 of MPA (43 Ϯ 9 versus 58 Ϯ 22 mg/h per L; P ϭ 0.045). It is noteworthy that the trough levels and AUC 0-12 of CsA and MPA were similar for the patients who did or did not present borderline changes on their randomization biopsy (data not shown), indicating that borderline changes and the pharmacokinetic profile of the immunosuppressive drugs were independent. Univariate Cox regression analysis confirmed that borderline changes, MPA trough levels, and AUC 0-12 were related to the occurrence of AR after CsA withdrawal (Table 5 ). However, MPA trough levels and AUC 0-12 were positively correlated (r 2 ϭ 0.54, P Ͻ 0.001; data not shown), and after multivariate analysis, only borderline changes and MPA AUC 0-12 remained significant risk factors for AR in the MMF group (Table 5) .
Conversely, in the CsA group, in which only three patients experienced AR, no risk factor of AR was identified. Actually, neither pharmacokinetic profiles of CsA or MPA nor the incidence of borderline changes was predictive of AR in this group (data not shown).
Then we applied Cox regression analysis to the entire group (108 patients). To test potential interactions between treatment, borderline changes, and MPA AUC 0-12 , we categorized MPA AUC 0-12 into low (Ͻ50 mg/h per L) and high (Ͼ50 mg/h per L) AUC. A 50-mg/h per L cutoff value was chosen to take into account the 95% confidence intervals of the mean MPA AUC 0-12 of the patients who experienced rejection after CsA withdrawal (37.4 to 49.0) compared with the rejection-free patients in the MMF group (51.4 to 64.3). Univariate analysis showed that treatment group (MMF); MPA trough levels; MPA AUC 0-12 ; and the interactions between treatment and borderline changes, treatment and MPA AUC 0-12 , and borderline changes and MPA AUC 0-12 were significantly associated with the occurrence of AR. However, only MPA AUC 0-12 and the combination variable between treatment and borderline changes remained significant independent risk factors in the multivariate model, whereas interaction between treatment and MPA AUC 0-12 and MPA AUC 0-12 and borderline changes became nonsignificant (Table 6 ).
Discussion
In this study, we tried to identify retrospectively the potential factors that could have predicted the occurrence of AR after CsA discontinuation. Multivariate analysis showed that the presence of borderline changes at 3-mo protocol biopsy and a low AUC of MPA at the time of randomization (3 mo) were two independent factors associated with the risk for AR in the MMF group. In the present study, eligible patients were selected carefully, corresponding to low-risk patients: First transplant, panel reactive antibodies Ͻ30%, and no AR during the first 3 mo posttransplantation. Finally, Ͻ50% (108 of 218) of the eligible recipients at the time of the graft could be randomized at 3 mo posttransplantation. However, despite this preselection, the incidence of AR was significantly increased after CsA withdrawal in the MMF group. Furthermore, renal function at 1 yr was significantly altered after these AR episodes, although most had a low histologic grade (nine of 10 had grade 1). This finding could be related to the fact that AR occurred relatively late after transplantation (167 Ϯ 42 d). Indeed, previous reports have shown that late AR have a deleterious impact, especially when they occur after days 60 to 90 posttransplantation (15, 16) .
Few authors have investigated the risk factors of AR in a strategy of CsA discontinuation. Anjum et al. (17) reported an increased risk for patients with both two HLA-B and two HLA-DR mismatches. The measurement of the frequency of precursor cytotoxic T lymphocytes in the peripheral blood could allow identification of patients in whom minimization of immunosuppression can be achieved safely (9, 18) . However, this test cannot be performed easily in a routine practice.
The clinical significance of borderline changes remains controversial and must be interpreted carefully according to the context. Meehan et al. (19) reported that the spontaneous outcome of borderline changes was favorable in 72% of the cases. However, many studies suggest that borderline changes should be treated with antirejection therapy when associated with a graft dysfunction (20 -23) , but the usefulness of this treatment has been discussed (24) . As reported recently, the time of occurrence of borderline changes could also influence the outcome. Most of the very early (day 7) untreated borderline changes progress to AR, whereas later (day 28) diagnosed borderline changes behave favorably (25) . Our study revealed a 27% (29 of 108) incidence of borderline changes among stable recipients at 3 mo posttransplantation, comparable to previously reported studies (26, 27) . In these patients, minimization of immunosuppressive treatment had different consequences according to the drug withdrawn. Only one of 16 patients in the CsA group progressed to AR after MMF discontinuation compared with five of 13 in the MMF group after CsA withdrawal Figure 2 . Probability of acute rejection after mycophenolate mofetil (MMF; solid line) or cyclosporine (CsA; dashed line) withdrawal. At 1 yr, the risk is 18.5% in the MMF group and 5.6% in the CsA group (P ϭ 0.045).
(P ϭ 0.047). The Cox multivariate analysis of the entire population confirmed the interaction between MMF treatment and the presence of borderline changes on the randomization biopsy. These results suggest that in 3-mo stable patients, borderline changes do not require antirejection therapy. Moreover, in this situation, a progressive MMF discontinuation seems to be a safe procedure, unlike CsA withdrawal.
Several authors have reported a significant correlation between the MPA pharmacokinetic profile and the incidence of AR in the early posttransplantation period (28 -31) . In selected rejection-free patients of our study, a low MPA AUC seems to be a reliable predictor of AR, considering patients in whom CsA is withdrawn at 3 mo. This result confirms a close relationship between MMF efficacy and its pharmacokinetic profile and underlines the need for this drug monitoring, especially in a strategy of CsA elimination.
Thus, considering the incidence of AR previously reported in different randomized trials (11) (12) (13) and in our study, the new immunosuppressive drug MMF did not lead to a completely safe CsA discontinuation. Otherwise, the two pivotal trials of CsA elimination conducted with sirolimus showed different results. Gonwa et al. (32) found a similar incidence of AR at 1 yr for patients who were withdrawn from CsA Nevertheless, all of these trials mentioned a significant increase of GFR, especially in patients who were withdrawn successfully from CsA. Because renal function at 1 yr is a surrogate marker for long-term graft survival (34) , this points out the need to screen better the eligible patients to improve the safety of this procedure. Actually, early episodes of AR could be a risk factor for CsA discontinuation that could explain the different results observed in the two very similar trials with sirolimus (32, 33) .
In conclusion, our study shows that early CsA withdrawal under MMF therapy leads to a trend toward an improvement of renal function at 1 yr posttransplantation. However, this protocol is associated with an increased risk for AR. One can hypothesize that this risk could be reduced if eligible patients are selected carefully. A systematic graft biopsy and a MPA pharmacokinetic profile should be performed to exclude from this strategy the recipients who present borderline changes and/or a low MPA AUC. Our results suggest a cutoff value at 50 mg/h per L that needs to be confirmed by further investigations. Because a 12-h AUC is not easy to perform in routine clinical practice, MPA exposure could be assessed by a limited sampling strategy as proposed by van Hest et al. (35) . According to these criteria, 50 to 60% of the patients who received a transplant in our center could achieve CsA discontinuation successfully.
